Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs. However, the new study led by Ziyad Al-Aly, a physician-scientist at the Veterans Affairs St ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...